FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults Read more
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to FDA Read more
FDA Approves IBRANCE (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer Read more
Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia Read more
Editas and BlueRock Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms Read more